Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes
Sponsor
Shahid Beheshti University of Medical Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT01028443
Collaborator
(none)
2
2
Study Details
Study Description
Brief Summary
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Study Type:
Interventional
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Cyclosporine A 2%
|
Drug: Sandimmune
|
| Placebo Comparator: Artificial tears
|
Drug: Artelose
|
Outcome Measures
Primary Outcome Measures
- The rate of rejection after drop sessation [3 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- Penetrating keratoplasty in eyes without vascularization
Exclusion Criteria:
- History of previous intraocular surgery
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ophthalmic Research Center | Tehran | Iran, Islamic Republic of | 166666 | |
| 2 | Ophthalmic Research Center | Tehran | Iran, Islamic Republic of | 16666 |
Sponsors and Collaborators
- Shahid Beheshti University of Medical Sciences
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT01028443
Other Study ID Numbers:
- 8546
First Posted:
Dec 9, 2009
Last Update Posted:
Dec 9, 2009
Last Verified:
Apr 1, 2006
Additional relevant MeSH terms: